Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Advances in Hematology & OncologyCases in the Management of Polycythemia Vera: Switching From Hydroxyurea to Ruxolitinib to Resolve Symptoms and Improve Quality of Life

In this first part of a three-case series, a 65-year-old man received ruxolitinib for treatment and reported feeling much better after one month, and after two months of treatment, most of his symptoms had completely resolved and his blood cell counts were maintained under control.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form